Information Provided By: 
Fly News Breaks for February 16, 2018
ACOR
Feb 16, 2018 | 06:10 EDT
Piper Jaffray analyst Charles Duncan last night upgraded Acorda Therapeutics and raised his price target for the shares to $37 from $32. The analyst, based on diligence in the Parkinson's space, has "enhanced conviction" that Inbrija can be a $700M-$800M drug in the U.S. alone. He sees a "risk-reduced regulatory path" ahead in the U.S. and Europe. Acorda closed yesterday down 50c to $25.10.
News For ACOR From the Last 2 Days
There are no results for your query ACOR
